Earnings Call · Q3 FY2022·2022-11-08

Q3 22EPS +44.95%·Rev n/aQ2 22EPS -56.82%·Rev n/aQ1 22EPS -9.92%·Rev n/aQ4 21EPS -56.25%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Thomas Hong — Investor Relations or IR Representative

Jacque Shea — President and CEO

Michael Sumner — Chief Medical Officer

Peter Kies — Chief Financial Officer

−0.5%1d on move date−1.0% vs SPY3d+10.7%5d+12.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access